{
  "ptid_time": "130_S_1290_2008-02-18",
  "img_path": "/data/qiuhui/data/adni/images/130_S_1290/2008-02-18/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 43,048 mm³, 16.5% above the reference mean. With a Z-score of 0.44 (67.2th percentile), this represents normal volume ; hippocampal volume measures 5,050 mm³, 22.2% below the reference mean. With a Z-score of -1.78 (3.7th percentile), this represents moderate atrophy; whole brain volume measures 868,197 mm³, 6.5% below the reference mean. With a Z-score of -0.78 (21.9th percentile), this represents normal volume ; entorhinal cortex volume measures 2,293 mm³, 33.8% below the reference mean. With a Z-score of -1.82 (3.4th percentile), this represents moderate atrophy; fusiform gyrus volume measures 16,085 mm³, 0.2% below the reference mean. With a Z-score of -0.01 (49.5th percentile), this represents normal volume ; middle temporal gyrus volume measures 16,608 mm³, 7.9% below the reference mean. With a Z-score of -0.70 (24.2th percentile), this represents normal volume . ",
  "text_data": "Age is 80.3 years. Gender is Female. Education: 8 years. MMSE: 19.0. Logical Memory: 0.0. Laboratory findings: Phosphorus: 4.90 (significant elevated). APOEε4 alleles: 1.0. Biomarker levels: Amyloid beta: 725.70 pg/mL (normal ); Total tau: 288.70 pg/mL (normal ); Phosphorylated tau: 27.01 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: AD.",
  "gpt_diagnosis": "**Reasoning:** The patient shows moderate atrophy in the hippocampus and entorhinal cortex, which are key regions affected in Alzheimer's disease (AD), alongside a low MMSE score (19/30) suggestive of cognitive impairment. However, normal Aβ, T-tau, and P-tau levels argue against typical AD pathology. The cognitive deficits may be due to another neurodegenerative process or mixed pathology.  \n\n**Diagnosis:** **Dementia** (likely non-AD etiology, such as hippocampal sclerosis or limbic-predominant age-related TDP-43 encephalopathy [LATE]).  \n\n**Confidence:** **Medium** (due to conflicting biomarkers—structural atrophy and cognitive decline are clear, but CSF biomarkers do not support AD).  \n\n*(Note: If vascular or other comorbidities are present, the diagnosis could shift. Clinical correlation with history/imaging is advised.)*",
  "timestamp": "2025-07-26T14:35:29.935552"
}